Skip to main content
GMAB
NASDAQ Life Sciences

Epcoritamab Phase 3 Smashes Primary Endpoint, Cuts DLBCL Progression Risk by 60%

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$26.02
Mkt Cap
$15.438B
52W Low
$20.225
52W High
$35.43
52W Position info
29% above low
Off High info
27% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

GMAB sits 29% above its 52-week low of $20.225.

Summary

Genmab announced highly positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival, reducing the risk of disease progression and death by 60%. This follows previous positive clinical trial news for epcoritamab in a different patient population in June, reinforcing the drug's potential. These strong efficacy results significantly de-risk the drug and pave the way for regulatory submissions, targeting a major cancer market.

At the time of this announcement, GMAB was trading at $26.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4B. The 52-week trading range was $20.23 to $35.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GMAB - Latest Insights

GMAB
Oct 28, 2026, 9:41 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $45.12
Real-time Price: $56.06 info
Change: +$10.94 (+24%) info
Market Cap: $34.422B info
GMAB
Oct 26, 2026, 11:08 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $44.35
Real-time Price: $56.06 info
Change: +$11.71 (+26%) info
Market Cap: $34.422B info
GMAB
Oct 26, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $45.35
Real-time Price: $56.06 info
Change: +$10.71 (+24%) info
Market Cap: $34.422B info
GMAB
Oct 23, 2026, 11:56 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $40.64
Real-time Price: $56.06 info
Change: +$15.42 (+38%) info
Market Cap: $34.422B info
GMAB
Oct 13, 2026, 6:22 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $37.66
Real-time Price: $56.06 info
Change: +$18.40 (+49%) info
Market Cap: $34.422B info